These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 12885263)

  • 1. Whole body pharmacokinetic models.
    Nestorov I
    Clin Pharmacokinet; 2003; 42(10):883-908. PubMed ID: 12885263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?
    Bouzom F; Ball K; Perdaems N; Walther B
    Biopharm Drug Dispos; 2012 Mar; 33(2):55-71. PubMed ID: 22228149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically based pharmacokinetic modeling of nanoparticles.
    Li M; Al-Jamal KT; Kostarelos K; Reineke J
    ACS Nano; 2010 Nov; 4(11):6303-17. PubMed ID: 20945925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-body physiologically based pharmacokinetic models.
    Nestorov I
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):235-49. PubMed ID: 17428153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development.
    Edginton AN; Theil FP; Schmitt W; Willmann S
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1143-52. PubMed ID: 18721109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of PBPK modelling in drug discovery and development at Pfizer.
    Jones HM; Dickins M; Youdim K; Gosset JR; Attkins NJ; Hay TL; Gurrell IK; Logan YR; Bungay PJ; Jones BC; Gardner IB
    Xenobiotica; 2012 Jan; 42(1):94-106. PubMed ID: 22035569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The successes and failures of physiologically based pharmacokinetic modeling: there is room for improvement.
    Poggesi I; Snoeys J; Van Peer A
    Expert Opin Drug Metab Toxicol; 2014 May; 10(5):631-5. PubMed ID: 24517185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings.
    Lu G; Abduljalil K; Jamei M; Johnson TN; Soltani H; Rostami-Hodjegan A
    Curr Drug Metab; 2012 Jul; 13(6):695-720. PubMed ID: 22452453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making.
    Tan YM; Worley RR; Leonard JA; Fisher JW
    Toxicol Sci; 2018 Apr; 162(2):341-348. PubMed ID: 29385573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
    Poulin P; Theil FP
    J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically based pharmacokinetic (PBPK) modeling in children.
    Barrett JS; Della Casa Alberighi O; Läer S; Meibohm B
    Clin Pharmacol Ther; 2012 Jul; 92(1):40-9. PubMed ID: 22669290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development.
    Charnick SB; Kawai R; Nedelman JR; Lemaire M; Niederberger W; Sato H
    J Pharmacokinet Biopharm; 1995 Apr; 23(2):217-29. PubMed ID: 8719238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of "Physiologically Based Pharmacokinetic Model (PBPK)" New Approach Methodology (NAM) in Pharmaceuticals and Environmental Chemical Risk Assessment.
    Deepika D; Kumar V
    Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36834167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PBPK model reporting template for chemical risk assessment applications.
    Tan YM; Chan M; Chukwudebe A; Domoradzki J; Fisher J; Hack CE; Hinderliter P; Hirasawa K; Leonard J; Lumen A; Paini A; Qian H; Ruiz P; Wambaugh J; Zhang F; Embry M
    Regul Toxicol Pharmacol; 2020 Aug; 115():104691. PubMed ID: 32502513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.
    Khalil F; Läer S
    J Biomed Biotechnol; 2011; 2011():907461. PubMed ID: 21716673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically based pharmacokinetic modelling to guide drug delivery in older people.
    Chetty M; Johnson TN; Polak S; Salem F; Doki K; Rostami-Hodjegan A
    Adv Drug Deliv Rev; 2018 Oct; 135():85-96. PubMed ID: 30189273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An introduction to physiologically-based pharmacokinetic models.
    Upton RN; Foster DJ; Abuhelwa AY
    Paediatr Anaesth; 2016 Nov; 26(11):1036-1046. PubMed ID: 27550716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically Based Pharmacokinetics Model in Pregnancy: A Regulatory Perspective on Model Evaluation.
    Coppola P; Kerwash E; Cole S
    Front Pediatr; 2021; 9():687978. PubMed ID: 34249817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.